Filing Details
- Accession Number:
- 0001144204-15-040971
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-07-02 21:54:07
- Reporting Period:
- 2015-06-30
- Filing Date:
- 2015-07-02
- Accepted Time:
- 2015-07-02 21:54:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1072379 | Northwest Biotherapeutics Inc | NWBO | Pharmaceutical Preparations (2834) | 943306718 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1626920 | Cognate Bioservices, Inc. | 7513 Connelley Drive Hanover MD 21076 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 | Disposition | 2015-06-30 | 650,000 | $4.00 | 19,578,482 | No | 4 | S | Direct | |
Common Stock, Par Value $0.001 | Disposition | 2015-06-30 | 1,118,092 | $4.22 | 18,460,390 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Cognate entered into a $3 million convertible debt financing with an unrelated third party investor, secured by Cognate assets. The debt was convertible, at the investors' election, into common shares of Northwest Biotherapeutics restricted stock owned by Cognate. The third party investors elected to convert the debt and receive repayment in Common Shares rather than in cash. Therefore, on June 30, 2015, Cognate transferred 650,000 restricted common shares of Northwest Biotherapeutics, Inc.to this third party to settle the debt..
- Does not include 10,432,387 shares of common stock underlying currently exercisable warrants.
- Cognate entered into two convertible loans, each in the amount of $2,500,000, to an unrelated third party investor in June and July, 2014, and provided the proceeds of the financings for Northwest Biotherapeutics programs. The debt was secured by shares of Northwest Biotherapeutics owned by Cognate and was convertible, at the investors' election, into Northwest Biotherapeutics, Inc. common shares owned by Cognate at a fixed conversion price. The third party investors elected to take repayment in Common Shares rather than in cash. Therefore, on June 30, 2015, Cognate transferred 1,118,092 Common Shares to settle the debt notes..